These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 31986033)
1. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability. Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033 [TBL] [Abstract][Full Text] [Related]
2. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability. Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650 [TBL] [Abstract][Full Text] [Related]
3. SAR Matrices Enable Discovery of Mixed Efficacy μ-Opioid Receptor Agonist Peptidomimetics with Simplified Structures through an Aromatic-Amine Pharmacophore. Henry S; Anand JP; Brinkel AC; McMillan DM; Twarozynski JJ; Loo CE; Traynor JR; Mosberg HI ACS Chem Neurosci; 2021 Jan; 12(1):216-233. PubMed ID: 33346631 [TBL] [Abstract][Full Text] [Related]
4. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands. Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026 [TBL] [Abstract][Full Text] [Related]
5. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy. Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483 [TBL] [Abstract][Full Text] [Related]
6. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands. Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects. Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286 [TBL] [Abstract][Full Text] [Related]
8. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration. Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503 [TBL] [Abstract][Full Text] [Related]
9. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors. Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309 [TBL] [Abstract][Full Text] [Related]
10. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities. Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands. Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain. Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442 [TBL] [Abstract][Full Text] [Related]